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Introduction
In ANCA-associated vasculitides (AAVs) cyclophospha-
mide (CYC) is part of the standard therapy regimen for
severe manifestations. Rituximab (RTX) is effective in the
treatment of AAVs. No data on the cumulative effect of a
sequential treatment with CYC and rituximab on immu-
noglobulin levels in AAV are available. Such data are of
great interest since both therapies can induce hypogam-
maglobulinemia leading to an increased risk of infections
worsening the overall outcome.
Objective and methods
Retrospective analysis of the impact of immunosuppressive
therapy with CYC and RTX on serum immunoglobulin
(Ig) concentrations and peripheral B cells in patients with
AAV.
Methods and patients
Ig levels were analyzed in AAV patients either treated
with CYC alone or treated with CYC and RTX. The effect
of CYC on Ig levels was assessed in study group A
(n=26), while the impact of RTX treatment alone was
examined in study group B (n=29). In patients previously
treated with CYC followed by RTX we compared changes
in Ig concentrations prior to CYC to those after RTX
treatment (group C; n=15). The median CYC doses were
8.05±0.56 g, 18.76±14.55 and 13.11±13.27 g in groups A,
B and C and median RTX doses in group B and C were
1.8±0.8 g and 1.97±1.04 g respectively. The mean predni-
sone equivalent in patients treated with RTX was 12.35±
7.52 mg/day. Statistics: Mann Whitney U Test, if not
indicated otherwise.
Results
Mean Ig levels (mg/dL) prior to CYC therapy were nor-
mal. Means and standard deviations (SD) for group A
are: IgG: 11.84±3.24, IgM: 1.31±0.94, IgA: 2.46±1.19.
After CYC treatment IgG, IgM and IgA significantly
decreased to 8.6±2.51 (p=<0.001; t-test), 0.88±0.53
(p=0.048), and 1.74±0.6 (p=0.021) respectively. In group
B, median IgG levels prior to RTX were 9.74±3.49, IgM
levels 0.81±0.45 and IgA levels 2.3±1.15. Over a period
of 6 months after treatment, IgG significantly declined
to 7.45±2.79 (p=0.001), IgM to 0.52±0.35 (p=0.003) and
IgA to 1.69±0.81 (p=0.003). When assessing the effect of
RTX therapy following CYC (group C) we observed
the strongest decrease of all 3 isotypes: median IgG
levels of 12.68±4.29mg/dL prior to CYC decreased to
6.59±1.98mg/dL (p=<0.001) after the dual treatment,
IgM of 1.15±0.68 mg/dL to 0.52±0.42 mg/dL (p=0.002),
and IgA of 2.65±1.25 mg/dL to 1.56±0.78 mg/dL
(p=0.007). Follow-up measurements after RTX treat-
ment did not show an increase in Ig levels within 24
months. RTX led to a complete depletion of B cells
(</=2/µl) in all patients within the first 3 months after
therapy. Interestingly, in all 7 patients that were avail-
able for analysis of peripheral B cell numbers 24 months
after last RTX treatment, a persistent B lymphocytope-
nia with mean a B-cell count of 3.2/µl±1,7 was detected.
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Conclusions
In patients with AAV, treatment with CYC leads to a
decline in immunoglobulin levels, which is profoundly
aggravated by subsequent RTX treatment. Data in our
cohort furthermore indicates that B cell repopulation in
AAV patients after RTX treatment might be delayed.
Hence, Ig concentrations should be assessed after com-
bined treatment with CYC and RTX.
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